Advances in Medicine (AIM) 2025
24 May - 25 May, 2025, Hong Kong
Blood-based biomarkers (BBBs) may potentially aid earlier detection of Alzheimer’s disease (AD) following a recent revision of diagnostic criteria supporting core biomarker–based diagnosis. Initial local experience with lecanemab, a disease-modifying therapy (DMT) for patients with mild cognitive impairment or mild dementia due to AD, was shared at Advances in Medicine (AIM) 2025.
